CoChat

Approach to the treatment of multiple myeloma: a clash of philosophies

Open access
Rajkumar, S. Vincent, Gahrton, Gösta, Bergsagel, P. Leif · 2011 · Blood
Cited by 137

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

In this Perspective, we summarize some of the most contentious issues surrounding diagnosis and treatment of myeloma. We outline how a fundamental clash of philosophies, cure versus control, may be at the heart of many of the controversies. From the very definition of the disease to risk stratification to the validity of current clinical trial endpoints, we highlight the major areas of debate and provide alternative viewpoints that have implications for trial design and interpretation, as well as clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-06-297853

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 40

  1. Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies., Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
  2. Kyle, 2009, Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma., Leukemia, 23, 3, 10.1038/leu.2008.291 · DOI · Paper page
  3. Russell, 2011, Multiple myeloma and the road to personalised medicine., Lancet Oncol, 12, 617, 10.1016/S1470-2045(11)70143-7 · DOI
  4. Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [see comment]., N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
  5. Morgan, 2010, First-line and ongoing treatment with zoledronic acid improves overall survival in patients with multiple myeloma: results of the MRC IX Randomised Controlled Trial., Lancet, 376, 1989, 10.1016/S0140-6736(10)62051-X · DOI · Paper page
  6. Gahrton, 2009, Tandem autologous (ASCT)/allogeneic reduced intensity conditioning transplantation (RIC) with identical sibling donor versus ASCT in previously untreated multiple myeloma (MM): long term follow up of a prospective controlled trial by the EBMT [abstract]., ASH Annual Meeting Abstracts, 114, 52
  7. Shah, 2009, Proteasome inhibitors in the treatment of multiple myeloma., Leukemia, 23, 1964, 10.1038/leu.2009.173 · DOI · Paper page
  8. Tannock, 1983, Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results., J Clin Oncol, 1, 66, 10.1200/JCO.1983.1.1.66 · DOI
  9. Booth, 2008, Reflections on medical oncology: 25 years of clinical trials. Where have we come and where are we going?, J Clin Oncol, 26, 6, 10.1200/JCO.2007.13.8156 · DOI
  10. Saltz, 2008, Progress in cancer care: the hope, the hype, and the gap between reality and perception., J Clin Oncol, 26, 5020, 10.1200/JCO.2008.17.6198 · DOI
  11. Bergsagel, 2005, Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma., Blood, 106, 296, 10.1182/blood-2005-01-0034 · DOI · Paper page
  12. Fonseca, 2009, International Myeloma Working Group molecular classification of multiple myeloma: spotlight review., Leukemia, 23, 2210, 10.1038/leu.2009.174 · DOI · Paper page
  13. Harousseau, 2009, The role of complete response in multiple myeloma., Blood, 114, 3139, 10.1182/blood-2009-03-201053 · DOI · Paper page
  14. Nooka, 2009, The importance of complete response in outcomes in myeloma., Cancer J, 15, 465, 10.1097/PPO.0b013e3181c51cd4 · DOI
  15. Zhou, 2009, The molecular characterization and clinical management of multiple myeloma in the post-genome era., Leukemia, 23, 1941, 10.1038/leu.2009.160 · DOI · Paper page
  16. Nair, 2010, Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance., Blood, 115, 4168, 10.1182/blood-2009-11-255620 · DOI · Paper page
  17. Barlogie, 2010, Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences., J Clin Oncol, 28, 1209, 10.1200/JCO.2009.25.6081 · DOI · Paper page
  18. Gahrton, 1995, Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma., J Clin Oncol, 13, 1312, 10.1200/JCO.1995.13.6.1312 · DOI · Paper page
  19. Chanan-Khan, 2010, Importance of achieving a complete response in multiple myeloma, and the impact of novel agents., J Clin Oncol, 28, 2612, 10.1200/JCO.2009.25.4250 · DOI · Paper page
  20. van de Velde, 2007, Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma., Haematologica, 92, 1399, 10.3324/haematol.11534 · DOI · Paper page
  21. Harousseau, 2010, Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone., Blood, 116, 3743, 10.1182/blood-2010-03-275800 · DOI · Paper page
  22. Gay, 2011, Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., Blood, 117, 3025, 10.1182/blood-2010-09-307645 · DOI · Paper page
  23. Haessler, 2007, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling., Clin Cancer Res, 13, 7073, 10.1158/1078-0432.CCR-07-0527 · DOI · Paper page
  24. Weiss, 2009, A monoclonal gammopathy precedes multiple myeloma in most patients., Blood, 113, 5418, 10.1182/blood-2008-12-195008 · DOI · Paper page
  25. Corradini, 2003, Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma., Blood, 102, 1927, 10.1182/blood-2003-01-0189 · DOI
  26. Harousseau, 2010, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III Trial., J Clin Oncol, 28, 4621, 10.1200/JCO.2009.27.9158 · DOI · Paper page
  27. Ludwig, 2009, Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma., Blood, 113, 3435, 10.1182/blood-2008-07-169565 · DOI · Paper page
  28. Palumbo, 2009, A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract]., ASH Annual Meeting Abstracts, 114, 613
  29. Palumbo, 2010, A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥ 65 years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens [abstract]., ASH Annual Meeting Abstracts, 116, 622
  30. Anderson, 2007, Clinically relevant end points and new drug approvals for myeloma., Leukemia, 22, 231, 10.1038/sj.leu.2405016 · DOI · Paper page
  31. Orlowski, 2007, Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression., J Clin Oncol, 25, 3892, 10.1200/JCO.2006.10.5460 · DOI · Paper page
  32. Attal, 2010, Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005-02 [abstract]., ASH Annual Meeting Abstracts, 116, 310
  33. McCarthy, 2010, Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104 [abstract]., ASH Annual Meeting Abstracts, 116, 37
  34. Myeloma Trialists' Collaborative Group, 1998, Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials., J Clin Oncol, 16, 3832, 10.1200/JCO.1998.16.12.3832 · DOI · Paper page
  35. Cavo, 2010, Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study., Lancet, 376, 2075, 10.1016/S0140-6736(10)61424-9 · DOI · Paper page
  36. Food and Drug Administration, 2011, Revlimid (lenalidomide): ongoing safety review.
  37. Korn, 2011, Overall survival as the outcome for randomized clinical trials with effective subsequent therapies., J Clin Oncol, 29, 2439, 10.1200/JCO.2011.34.6056 · DOI
  38. Rajkumar, 2008, Treatment of myeloma: cure vs control., Mayo Clinic Proc, 83, 1142, 10.4065/83.10.1142 · DOI · Paper page
  39. Kumar, 2009, Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines., Mayo Clinic Proc, 84, 1095, 10.4065/mcp.2009.0603 · DOI · Paper page
  40. Gatenby, 2009, A change of strategy in the war on cancer., Nature, 459, 508, 10.1038/459508a · DOI · Paper page

Cited by

See all 137

Metadata

Authors
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L.
Venue
Blood
Published
2011-09-22
Volume
118
Issue
12
Pages
3205-3211
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2185344664
Cited by
137
References
16
FWCI
14.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Approach to the treatment of multiple myeloma: a clash of philosophies. https://app.cochat.ai/papers/10.1182/blood-2011-06-297853
The paper
Rajkumar, S. V., Gahrton, G., & Bergsagel, P. L. (2011). Approach to the treatment of multiple myeloma: a clash of philosophies. Blood. https://doi.org/10.1182/blood-2011-06-297853

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.